Immunologie verbindt de behandeling van vele ... - FarmaActueel

farmaactueel.nl

Immunologie verbindt de behandeling van vele ... - FarmaActueel

Biologicals: Psoriasisname type target Fase ofdevelopmentAlefacept (Amevive) biological Υ T cells (CD2) Approved 2003Efalizumab (Raptiva) biological Υ T cells (CD11a) Approved 2003PMLWithdrawn 2009Etanercept (Enbrel) biological Υ TNF-α Approved 2004Infliximab (Remicade) biological Υ TNF-α Approved 2006Adalimumab (Humira) biological Υ TNF-α Approved 2008Ustekinumab (Stelara) biological Υ IL-12, IL-23 Approved 2009Biologicals in the pipeline for Psoriasisname type target Fase ofdevelopmentBrodalumab biological Υ IL-17 receptor Fase IIIIxekizumab, secukinumab biological Υ IL-17 Fase IIIMK-3222 biological Υ IL-23 Fase IIIApremilast Small molecule PDE4 Fase IIITofacitinib Small molecule JAK Fase III6

More magazines by this user
Similar magazines